Tuesday, February 01, 2011

Another New Cancer Drug in Trial Testing

Good news!  There's another new drug presently in a trial testing stage for RCC patients.  It's name is


There is presently a study ongoing to compare Tivozanib to Sorafenib (Nexavar) in subjects with advanced renal cell carcinoma.      http://clinicaltrials.gov/ct2/show/NCT01030783

AVEO Pharmaceuticals, Inc., manufacturer of Tivozanib have announced today that it has initiated patient enrollment in a multi-center Phase 2 exploratory biomarker study of Tivozanib, its lead product candidate designed to optimally block the VEGF pathway by inhibiting all three VEGF receptors, in patients with renal cell carcinoma (RCC).

Tivozanib is being tested for it's effectiveness on RCC and breast cancer patients.

So all of this is great news. A few months ago, I read about a new cancer drug that was looming on the horizon with the very high tech name of RAD0001.....seemed like something out of a Star War movie.  This drug later became known as Everolimus aka Afinitor which is one of today's leading cancer drugs for RCC. 

My point in all of this is that you can never give up.  RCC patients have been very fortunate for all of the treatment advances that have been made in renal cancer since 2006.  

Lesson learned here is to NOT QUIT......even though sometimes the going can get very tough!

1 comment:

Sonya said...

I try to keep up with the various drugs but didn't know about this one.